UPDATE: Morgan Stanley Reiterates on Pfizer as Vaccine Pipeline is Under-Appreciated
In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), and raised the price target from $34.00 to $36.00.
In the report, Morgan Stanley noted, “We believe Pfizer can outperform the pharma group given its potential for positive pipeline news and strategic action. Mgmt is committed to share repurchase and dividend increases. Financial and strategic action should continue to drive shareholder value.”
Pfizer closed on Thursday at $31.12.
Latest Ratings for PFE
|Apr 2016||Goldman Sachs||Reinstates||Neutral|
|Apr 2016||JP Morgan||Assumes||Overweight|
|Apr 2016||Morgan Stanley||Assumes||Equal-weight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.